Pathology Tests Become More Accessible at Government Hospitals in Madhya Pradesh

IMT News Desk
IMT News Desk
· 2 min read
Pathology tests in Madhya Pradesh’s government hospitals are now 80–85% cheaper and faster, covering 85 labs across the state under a Science House Medical collaboration; spokesperson Mr. Puneet Dubey, CEO, highlights improved access, quality, and NABL‑aligned diagnostics.

The Government of Madhya Pradesh has partnered with Science House Medical Pvt Ltd to bring affordable, high‑quality pathology services to government hospitals across the state, sharply cutting diagnostic costs and improving access.

85 labs, large‑scale reach

The initiative covers 85 laboratories spread across Madhya Pradesh and has already benefited around 1.6 crore people, with an estimated 10–12 lakh tests conducted every month. This expansion is making reliable diagnostic testing more available in both urban and rural areas.

Up to 85% lower test prices

Diagnostic costs have fallen by nearly 80–85%, with many common tests now available at a fraction of private‑sector rates. For instance, a test that typically costs about ₹100 in the private sector is now available for roughly ₹18 at government facilities, significantly easing the financial burden on patients.

Faster reports and stronger quality

The average report turnaround time has been streamlined to within 24 hours, enabling quicker diagnosis and treatment decisions. The program uses integrated laboratory systems and live dashboards monitored by the National Health Mission (NHM) for real‑time tracking and quality control. Science House Medical has also helped 36 government labs achieve NABL accreditation, ensuring tests follow standardized, quality‑aligned procedures.

Spokesperson on access and affordability

Mr. Puneet Dubey, CEO of Science House Medical Pvt Ltd, said the collaboration aims to bridge diagnostic‑access gaps across the state. “The focus remains on making reliable pathological diagnostics accessible at the lowest possible cost, using NABL‑aligned protocols and strict quality control,” he noted, adding that growth in domestic manufacturing of equipment and reagents has helped drive down prices while maintaining quality.

Read Next

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care
News
July 17, 2026

Menthra launches Menthra Care in India, the human layer that turns everyday support into real continuity of care

Menthra, an AI-powered emotional wellbeing platform, today announced the launch of Menthra Care in India, expanding its platform to connect users with verified therapists, coaches, licensed clinical professionals and care organisations when they need support beyond an AI companion. The launch follows Menthra’s India debut in June, which saw tens of thousands of users join […]
Article by: IMT News Desk
IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care
News
July 17, 2026

IHH FutureHealth Now 2026 Explores How Affordability, AI and Precision Medicine Will Shape the Future of Care

Against a backdrop of geopolitical uncertainty, supply chain disruptions and rapid advances in artificial intelligence (AI) and precision medicine, FutureHealth.Now provided a platform for industry leaders to explore how innovation, technology and new models of care can help tackle rising healthcare costs, workforce pressures and growing demand for services across the region. At his opening […]
Article by: IMT News Desk
Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill
News
July 16, 2026

Novo Nordisk Wins EU Approval for Wegovy Weight-Loss Pill

Novo Nordisk has secured European Commission approval for its once-daily Wegovy pill, giving the Danish drugmaker a major boost in the fast-growing obesity-treatment market. The approval makes it the first oral GLP-1 weight-loss treatment cleared in the European Union for adults with obesity or overweight who also have at least one weight-related health condition. The […]
Article by: IMT News Desk
Sun Pharma Wins South Africa Approval to Launch Generic Ozempic
News
July 16, 2026

Sun Pharma Wins South Africa Approval to Launch Generic Ozempic

India’s Sun Pharmaceutical Industries has received approval from South Africa’s health regulator to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, expanding its presence in the fast-growing GLP-1 market. The South African Health Products Regulatory Authority’s clearance allows Sun Pharma to market the injectable treatment for […]
Article by: IMT News Desk